Celcuity

Celcuity Share Buybacks

The Share Buybacks of Celcuity (CELC) as of Oct 11, 2026 is 95.87 M USD. In the previous year, Share Buybacks was 82,182.00 USD — a change of 116,560.83% (higher).

Share Buybacks

95.87 MUSD

YoY

116,560.83%

Last updated:

Share Buybacks of Celcuity is 2022 95.87 M USD. Share Buybacks of Celcuity was 2021 82,182.00 USD. It decreases by 116,560.83% higher compared to the previous year.

The Celcuity Share Buybacks history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Share Buybacks
Date
Share Buybacks
Jan 1, 2015
3.80 M USD
Jan 1, 2016
3.72 M USD
Jan 1, 2017
24.11 M USD
Jan 1, 2018
-55,138.00 USD
Jan 1, 2019
266,335.00 USD
Jan 1, 2020
60,303.00 USD
Jan 1, 2021
82,182.00 USD
Jan 1, 2022
95.87 M USD
The Celcuity Share Buybacks history
YEARShare BuybacksYoY
95.87 MUSD+116,560.83%
82,182.00USD+36.28%
60,303.00USD-77.36%
266,335.00USD-583.03%
-55,138.00USD-100.23%
24.11 MUSD+548.46%
3.72 MUSD-2.21%
3.80 MUSD—
Access this data via the Eulerpool API

Celcuity Stock analysis

What does Celcuity do? Celcuity Inc is a biotechnology company founded by Brian Sullivan in 2012. The company is headquartered in Minneapolis, USA. The business model of Celcuity is based on researching and developing new diagnostic and treatment methods for various types of cancer. The company utilizes a proprietary technology platform called CELx, which enables the analysis of cancer cell signaling pathways and the development of individualized treatment strategies. Celcuity specializes in the development of diagnostics and personalized therapies based on individual cancer cell signaling pathways. The company operates in two divisions: 1. Diagnostics division: Celcuity's diagnostics division focuses on identifying new cancer markers and biomarkers for early detection of cancer and the development of individualized treatment strategies. 2. Therapy division: Celcuity's therapy division specializes in the development of personalized therapies based on individual cancer cell signaling pathways. Celcuity currently offers two products based on the CELx technology platform: 1. CELx HUB: CELx HUB is a cloud-based software that allows doctors and researchers to analyze cancer samples and develop individualized treatment strategies. 2. CELx TIL: CELx TIL is a diagnostic tool that measures the presence of tumor cells in the immune system of cancer patients. In summary, Celcuity Inc is a leader in the field of personalized cancer therapy based on individual cancer cell signaling pathways. The company has found a niche in this growing market and has a unique technology platform that allows it to serve its customers effectively. With its products and services, Celcuity is helping to revolutionize cancer treatment and improve the quality of life for cancer patients worldwide. Celcuity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celcuity stock

Share Buybacks of Celcuity is 95.87 M USD in 2022.

Share Buybacks of Celcuity changed from 82,182.00 USD to 95.87 M USD, representing a 116,560.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Share Buybacks Celcuity since 2006 – with annual values, charts, and detailed analysis.

Share buybacks represent the cash spent repurchasing the company's own shares. Buybacks reduce shares outstanding and can increase EPS.

Share Buybacks's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Share Buybacks's Celcuity historically and in real time.

Access this data via the Eulerpool API

Cash Flow — Celcuity

All Key Metrics — Celcuity